Transition from zinc salts to trientine tetrahydrochloride in a cohort of adult patients with Wilson disease: the ZICUP study
Aurélia Poujois, Mickael Alexandre Obadia, Nouzha Oussedik-Djebrani, Eduardo Couchonnal-Bedoya et autres
Wilson disease (WD) treatment aims to reduce copper accumulation in the liver and brain. Zinc salts (ZS) are often associated with gastrointestinal side effects, poor adherence, and reduced efficacy. Copper chelators, such as trientine tetrahydrochloride (TETA4), offer an alternative for patients who …
fr (code pays fourni par la source)